Kaplan Meier analysis demonstrated the OS rates in different FDX1 expression groups stratified by age (> 41 y vs. ≤ 41 y), gender (male vs. female), glioma grade (II, III, and IV), histology (low grade glioma [LGG] vs. glioblastoma multiforme [GBM]), tumor type (primary, recurrent, and secondary), 1p19q codeletion status (non-codeletion vs. codeletion), IDH mutation status (wildtype vs. mutant), and receipt of radiotherapy and chemotherapy (yes vs. no). The gene discussed is IDH1; the disease is central nervous system cancer.